All In Biotech

Drug Trial Radar · NCT06832202

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

A Phase II Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab Deruxtecan (T-DXd) in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients With Intolerable Adverse Reaction or Disease Progression on Standard of Care

Last checked: Nov 19, 2026Latest source record: Jun 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 16, 2025

Primary completion

Jun 1, 2027

Study completion Dec 1, 2029

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Feb 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II Study of HLX22 in Combination with Trastuzumab Deruxtecan (T-DXd) in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients with Disease Progression or Intolerable Adverse Reaction on Standard of Care. Eligible subjects will be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).

Conditions

  • HER2-low Hormone Receptor Positive Breast Cancer

Interventions

  • HLX22Drug

    HLX22 15mg/kg Q3W

  • Trastuzumab DeruxtecanDrug

    Trastuzumab Deruxtecan 5.4mg/kg Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to 5 years
  2. Objective response rate (ORR)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.